Lead Product(s): AAV-based gene therapy
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 08, 2021
Under the terms of the agreement, CEVEC grants Biogen a non-exclusive license for CEVEC’s ELEVECTA® Technology. The deal will afford Biogen the rights to use the technology across their portfolio of gene therapy products.